This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
Exploring Nasal Casts in Nasal Drug Development
Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights
Navigating the Shift to more sustainable Low GWP propellants in pMDIs
Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions
Optimizing Preclinical Studies for Intranasal and Pulmonary Programs
Webinars, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Market Insights, Product Solutions
In Silico Modelling for Orally Inhaled Drug Development (OINDP)
Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
